Table 2.

Results of the Network Meta-Analysis for Individual Kidney Outcomes

Variable	Placebo	DPP-4 inhibitors	SGLT2 inhibitors
Microalbuminuria
Placebo	1
DPP-4 inhibitors	0.80 (0.46–1.24)	1
SGLT2 inhibitors	0.64 (0.41–0.93)	0.80 (0.48–1.37)	1
Macroalbuminuria
Placebo	1
DPP-4 inhibitors	0.82 (0.44–1.33)	1
SGLT2 inhibitors	0.48 (0.24–0.72)	0.59 (0.27–1.07)	1
Worsening nephropathy
Placebo	1
DPP-4 inhibitors	0.82 (0.47–1.23)	1
SGLT2 inhibitors	0.65 (0.44–0.91)	0.79 (0.50–1.36)	1
End-stage kidney disease
Placebo	1
DPP-4 inhibitors	0.97 (0.71–1.40)	1
SGLT2 inhibitors	0.65 (0.46–0.98)	0.67 (0.42–1.11)	1

Values are expressed as median odds ratios (95% credible intervals).

DPP-4, dipeptidyl peptidase-4; SGLT2, sodium-glucose cotransporter 2.